When these CAR-T cells are combined with low doses of cabozantinib – a tyrosine kinase inhibitor (TKI) that significantly decreases PD-L1 expression and increases EGFR expression in RCC cells in vitro – 5-fold lower tumor volume were found when compared with CAR-NK92 cells or cabozantinib treatment alone [35]. The gene discussed is EGFR; the disease is neoplasm.